Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06899360
Recruiting Observational

Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.

NCT06899360 · tracked via the Priya Life Science Italy tracker
Sponsor
University of Udine
Phase
Observational
Started
2024-10-01
Last updated
2025-03-27

Condition(s) studied

Age-Related Macular Degeneration

Study summary

The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD). The study aims to analyze real-world clinical data to identify key predictors of disease progression and functional outcomes, with the goal of optimizing AMD management. The study involves 200 patients aged ≥50 with a confirmed diagnosis of AMD, monitored through routine clinical practice. Primary outcomes include progression rates to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life. Anti-VEGF therapy and AI-based fluid analysis will be integrated to explore their impact on disease progression and patient outcomes.

Eligibility

Sex
ALL
Min age
50 Years
Max age
120 Years
Healthy volunteers
No
Inclusion Criteria: * age ≥ 50 years. * confirmed diagnosis of AMD in at least one eye. * follow-up scheduled according to standard clinical practice. Exclusion Criteria: * presence of other significant ocular conditions that could affect visual acuity. * systemic conditions that make the patient unsuitable for long-term follow-up.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Ophthalmology Udine UD Recruiting

More University of Udine trials in Italy

Tumor Microenvironment in Ovarian Cancer Recruiting
Effect of the Consumption of Cookies Enriched With Plant Proteins and of a Vitamin D Supplement on the Progression of Sarcopenia in the Elderly Active, not recruiting
The Supplementation Therapy in Autism and Response to Treatment Study Recruiting
Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy Recruiting

Other trials for the same condition

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration Active, not recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) Recruiting
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06899360 on ClinicalTrials.gov ↗ ← All trials in Italy